Patent: 6,355,245
✉ Email this page to a colleague
Summary for Patent: 6,355,245
| Title: | C5-specific antibodies for the treatment of inflammatory diseases |
| Abstract: | The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system. |
| Inventor(s): | Evans; Mark J. (Cheshire, CT), Matis; Louis A. (Southport, CT), Mueller; Eileen Elliott (East Haven, CT), Nye; Steven H. (Mequon, WI), Rollins; Scott (Monroe, CT), Rother; Russell P. (Cheshire, CT), Springhorn; Jeremy P. (Cheshire, CT), Squinto; Stephen P. (Bethany, CT), Thomas; Thomas C. (Madison, CT), Wilkins; James A. (Woodbridge, CT) |
| Assignee: | Alexion Pharmaceuticals, Inc. (Cheshire, CT) |
| Application Number: | 08/487,283 |
| Patent Claims: | see list of patent claims |
Details for Patent 6,355,245
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | SOLIRIS | eculizumab | Injection | 125166 | 03/16/2007 | ⤷ Try a Trial | 2019-03-12 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 6,355,245
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Austria | 448791 | ⤷ Try a Trial |
| Australia | 2474795 | ⤷ Try a Trial |
| Brazil | 9507594 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
